Want to see TSE:AVCN full AI Analyst Report?
AVCN Stock Chart & Stats
C$0.13
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.13
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.10 - C$0.30
Previous CloseN/A
Volume5.03K
Average Volume (3M)46.34K
Market Cap
C$16.13M
Enterprise ValueC$25.16
Total Cash (Recent Filing)C$200.42K
Total Debt (Recent Filing)C$169.56K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding134,383,850
10 Day Avg. Volume46,048
30 Day Avg. Volume46,335
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginSustained gross margins above 50% suggest Avicanna's products can generate meaningful contribution after direct costs. This provides a foundation for future operating leverage if the company can scale revenue and control overhead.
Manageable LeverageA relatively modest debt burden limits near-term balance-sheet pressure and preserves financial flexibility. Stabilization from the stressed 2022–2023 period reduces solvency risk while management works toward sustainable profitability.
Historical Revenue Scale-UpThe substantial revenue expansion achieved through 2024 demonstrates that Avicanna has been able to build commercial scale in its regulated cannabinoid markets. That larger base can support operating leverage if growth resumes.
Bears Say
Persistent UnprofitabilityContinuing losses show that current revenue and gross profit are insufficient to cover operating expenses. Without material cost reduction or renewed growth, Avicanna may remain dependent on external financing and face limited equity value creation.
Ongoing Cash BurnPersistent operating and free-cash-flow deficits weaken financial self-sufficiency and constrain investment capacity. The larger TTM cash burn also indicates that the improvement seen in 2025 has not yet translated into a reliable path to cash break-even.
Stalling Revenue GrowthA shift from prior expansion to flat or declining revenue raises execution risk and makes fixed-cost absorption more difficult. Slower demand or limited market penetration could prolong losses and delay the benefits of the company's improved gross margin.
Avicanna News
AVCN FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was C$0.10 and its highest was C$0.30 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is C$16.13M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is Nov 12, 2026 which is in 67 days.
How were Avicanna’s earnings last quarter?
Avicanna released its earnings results on Aug 14, 2026. The company reported -C$0.008 earnings per share for the quarter.
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 134,383,850 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Avicanna reported an EPS of -C$0.008 in its last earnings report. Following the earnings report the stock price went down -3.704%.
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in TSE:AVCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―